

Proven Performance: From Discovery to Therapy

Prolific Publication

CleanCap[®] reagents are the premier mRNA capping technology trusted by scientists around the globe for vaccine and therapeutics development—ranging from clinical to commercial. In the last 7 years, CleanCap technology has been leveraged in hundreds of publications, confirming its position as an industry-leading technology.



700+ Publications in 7 years



5x Increase Annual Publications in 2015 vs. 2021



200+ Publications in 2021


A Quality Product Yields Quality Results

When science demands high-quality results for high-impact work, researchers trust their experiments to CleanCap reagents.

>60 High-impact Journals **13.6** Average Journal Impact Factor >85 Nature Family Publications

>40 *Cell* Family Publications

Scientists from **37** countries in **6** continents and **100s** of institutions have used CleanCap reagents to power new discoveries in a range of applications:



Enabling a New Era of Modernized mRNA Therapeutics Production

Driving Success from the Bench to Bedside and Everywhere in Between

CleanCap technology is trusted by hundreds of researchers across the globe from academic institutions to pharmaceutical companies—to support basic science and clinical research efforts in biology, chemistry, and bioengineering.



22/25 Top Global Universities



Revolutionizing mRNA Therapeutics

CleanCap reagents have enabled multiple therapeutics programs through the development process, supporting researchers from early discovery and clinical drug approval, to global manufacture and distribution.



Supporting the Leading COVID-19 Vaccine Program Around the Globe



Ready to get started?





part of Maravai LifeSciences

©2022 TriLink BioTechnologies. All Rights Reserved. Ver. 03.25.2022